MPD: Measures involving in vitro assay

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Cowell1:2	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from peritoneal fluid 24h post-infection (x 10³) (CFU/mL) [log(n/mL)] peritoneal_CFU 49002	inbred	13	f	8wks	N=5	2012

Cowell1:3	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from kidney 24h post-infection (CFU/g) [log(n/g)] kidney_CFU 49003	inbred	13	f	8wks	N=6	2012

CSNA03:685	CSNA03	in vitro assay	(none)	peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, founders [h] period_in 112539	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:686	CSNA03	in vitro assay	(none)	peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, CC [h] period_cc 112544	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:688	CSNA03	in vitro assay	(none)	specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, founders [n] phase_in 112540	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:689	CSNA03	in vitro assay	(none)	specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, CC [n] phase_cc 112545	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:691	CSNA03	in vitro assay	(none)	peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, founders [n/s] amplitude_in 112541	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:692	CSNA03	in vitro assay	(none)	peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, CC [n/s] amplitude_cc 112546	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:694	CSNA03	in vitro assay	(none)	number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, founders [days] damping_in 112542	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:695	CSNA03	in vitro assay	(none)	number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, CC [days] damping_cc 112547	CC w/par	40	both	8-12wks	N=4	2020

CSNA03:697	CSNA03	in vitro assay	(none)	percentage of observed rhythms that fit expected sine wave, indicating stability and robustness of circadian rhythm, in fibroblast cultures, founders [%] goodness_of_fit_in 112543	inbred w/CC8	8	both	8-12wks	N=9	2020

CSNA03:698	CSNA03	in vitro assay	(none)	percentage of observed rhythms that fit expected sine wave, indicating stability and robustness of circadian rhythm, in fibroblast cultures, CC [%] goodness_of_fit_cc 112548	CC w/par	40	both	8-12wks	N=4	2020

Dietrich1:1	Dietrich1	in vitro assay	Bacillus anthracis lethal toxin	susceptibility to Bacillus anthracis (0=susceptible, 1=resistant) [designation] anthrax_lethal_toxin 1501	inbred	50	f	6-8wks*		1998

Ferris1:6	Ferris1	in vitro assay	influenza A (H1N1) virus	viral replication log titer, day 4 post-infection (lung) [n] titer 47606	CC pre w/par	162	f	8-16wks	N=1	2012

Graham2:6	Graham2	in vitro assay	SARS-CoV	lung viral load titer (log10(x+1)), post infection [log(n)] log_titer 113790 post infection: day 2 day 4	CC RIX	111	f	8-10wks		2021

Gros1:1	Gros1	in vitro assay	Candida albicans	kidney fungal load 48h post-infection, colony-forming units (log₁₀ CFU per kidney) [log(n)] fungal_load 38501	inbred	23	f	8-12wks	N=9	2011

Gros1:2	Gros1	in vitro assay	Candida albicans	susceptibility to C. albicans based on fungal load (0=susceptible; 1=resistant) [designation] susceptibility 38502	inbred	23	f	8-12wks	N=9	2011

Powell1:1	Powell1	in vitro assay	Neisseria musculi	oral cavity bacterial colony count (CFU/swab) post inoculation (x 10³) [n] bacterial_load 62801 wk 1 wk 2 wk 3 wk 4 wk 5 wk 6 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12	inbred	8	both	8-16wks	N=12	2018

Rodriguez1:1	Rodriguez1	in vitro assay	(none)	spleen and liver murine cytomegalovirus genome levels (normalized to endogenous b-actin) [ratio] CMV_LEVELS 24101	QTL population		both	8-12wks	N=92	2009

Schughart4:83	Schughart4	in vitro assay	influenza A (H3N2) virus	viral load in lungs (titer, FFU per lung) log10 (x+1) [log(n)] titer_trt 58783 days post-infection: 3 5 8	inbred w/CC8	8	f	8-12wks	N=5	2016

Cowell1

in vitro assay

Staphylococcus aureus

log₁₀ bacterial colony count from peritoneal fluid 24h post-infection (x 10³) (CFU/mL) [log(n/mL)] peritoneal_CFU 49002

inbred

13

f

8wks

N=5

2012

Cowell1

in vitro assay

Staphylococcus aureus

log₁₀ bacterial colony count from kidney 24h post-infection (CFU/g) [log(n/g)] kidney_CFU 49003

inbred

13

f

8wks

N=6

2012

CSNA03

in vitro assay

(none)

peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, founders [h] period_in 112539

inbred w/CC8

8

both

8-12wks

N=9

2020

CSNA03

in vitro assay

(none)

peak-to-peak interval, indicating amount of time it takes for one cycle of bioluminescence circadian rhythm, in fibroblast cultures, CC [h] period_cc 112544

CC w/par

40

both

8-12wks

N=4

2020

CSNA03

in vitro assay

(none)

specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, founders [n] phase_in 112540

inbred w/CC8

8

both

8-12wks

N=9

2020

CSNA03

in vitro assay

(none)

specific time point when bioluminescence reaches highest circadian rhythm amplitude (cycle number), in fibroblast cultures, CC [n] phase_cc 112545

CC w/par

40

both

8-12wks

N=4

2020

CSNA03

in vitro assay

(none)

peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, founders [n/s] amplitude_in 112541

inbred w/CC8

8

both

8-12wks

N=9

2020

CSNA03

in vitro assay

(none)

peak-to-trough, indicating level of synchronization in circadian rhythm (max counts/s), in fibroblast cultures, CC [n/s] amplitude_cc 112546

CC w/par

40

both

8-12wks

N=4

2020

CSNA03

in vitro assay

(none)

number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, founders [days] damping_in 112542

inbred w/CC8

8

both

8-12wks

N=9

2020

CSNA03

in vitro assay

(none)

number of days required for circadian rhythm amplitude to decrease to 36% of initial value, in fibroblast cultures, CC [days] damping_cc 112547

CC w/par

40

both

8-12wks

N=4

2020

CSNA03

in vitro assay

(none)

percentage of observed rhythms that fit expected sine wave, indicating stability and robustness of circadian rhythm, in fibroblast cultures, founders [%] goodness_of_fit_in 112543

inbred w/CC8

8

both

8-12wks

N=9

2020

CSNA03

in vitro assay

(none)

percentage of observed rhythms that fit expected sine wave, indicating stability and robustness of circadian rhythm, in fibroblast cultures, CC [%] goodness_of_fit_cc 112548

CC w/par

40

both

8-12wks

N=4

2020

Dietrich1

in vitro assay

Bacillus anthracis lethal toxin

susceptibility to Bacillus anthracis (0=susceptible, 1=resistant) [designation] anthrax_lethal_toxin 1501

inbred

50

f

6-8wks*

1998

Ferris1

in vitro assay

influenza A (H1N1) virus

viral replication log titer, day 4 post-infection (lung) [n] titer 47606

CC pre w/par

162

f

8-16wks

N=1

2012

Graham2

in vitro assay

SARS-CoV

lung viral load titer (log10(x+1)), post infection [log(n)] log_titer 113790 post infection: day 2 day 4

CC RIX

111

f

8-10wks

2021

Gros1

in vitro assay

Candida albicans

kidney fungal load 48h post-infection, colony-forming units (log₁₀ CFU per kidney) [log(n)] fungal_load 38501

inbred

23

f

8-12wks

N=9

2011

Gros1

in vitro assay

Candida albicans

susceptibility to C. albicans based on fungal load (0=susceptible; 1=resistant) [designation] susceptibility 38502

inbred

23

f

8-12wks

N=9

2011

Powell1

in vitro assay

Neisseria musculi

oral cavity bacterial colony count (CFU/swab) post inoculation (x 10³) [n] bacterial_load 62801 wk 1 wk 2 wk 3 wk 4 wk 5 wk 6 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12

inbred

8

both

8-16wks

N=12

2018

Rodriguez1

in vitro assay

(none)

spleen and liver murine cytomegalovirus genome levels (normalized to endogenous b-actin) [ratio] CMV_LEVELS 24101

QTL population

both

8-12wks

N=92

2009

Schughart4

in vitro assay

influenza A (H3N2) virus

viral load in lungs (titer, FFU per lung) log10 (x+1) [log(n)] titer_trt 58783 days post-infection: 3 5 8

inbred w/CC8

8

f

8-12wks

N=5

2016

Filter Table Results